Skip to main content
Premium Trial:

Request an Annual Quote

Nucleix Wins €2.5M EU Grant for Lung Cancer Diagnostic

NEW YORK (GenomeWeb) — Israeli molecular diagnostics firm Nucleix announced today that it has won a €2.5 million ($2.9 million) Horizon 2020 grant from the European Commission to continue development of its lung cancer screening test.

The test, called Lung EpiCheck, uses changes in DNA methylation patterns in blood samples for the early detection of lung cancer. It is based on the same technology as the firm's recently CE-marked Bladder EpiCheck urine test for bladder cancer monitoring.

With the new funding, Nucleix said it expects to move Lung EpiCheck into US and European clinical trials around the beginning of 2019.

The company, which won a €50,000 Horizon 2020 grant for its EpiCheck technology in 2016, is also developing cirrhosis and pan-cancer diagnostics.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.